Insiders at Alnylam Pharmaceuticals sold $7.7m in stock, including CEO Yvonne Greenstreet selling $1.9m; potential warning sign for investors.

Insiders at Alnylam Pharmaceuticals sold $7.7m worth of stock in the past 12 months, with CEO Yvonne Greenstreet selling $1.9m in shares. This could be a potential warning sign for investors, as insiders' actions are often considered important indicators of the company's health. Alnylam's stock has recently increased by 47%, but investors should remain vigilant.